Exchange Traded Concepts LLC Has $1.25 Million Position in Organon & Co. $OGN

Exchange Traded Concepts LLC lifted its stake in Organon & Co. (NYSE:OGN) by 4.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,279 shares of the company’s stock after purchasing an additional 5,352 shares during the period. Exchange Traded Concepts LLC’s holdings in Organon & Co. were worth $1,251,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ransom Advisory Ltd acquired a new stake in shares of Organon & Co. in the first quarter valued at approximately $32,000. Brooklyn Investment Group increased its holdings in shares of Organon & Co. by 1,012.3% in the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock valued at $46,000 after purchasing an additional 2,794 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Organon & Co. in the first quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Organon & Co. during the 1st quarter worth $60,000. Finally, PARK CIRCLE Co grew its holdings in Organon & Co. by 640.7% during the 1st quarter. PARK CIRCLE Co now owns 4,000 shares of the company’s stock worth $60,000 after acquiring an additional 3,460 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

OGN opened at $10.58 on Tuesday. The company has a fifty day moving average price of $9.71 and a two-hundred day moving average price of $10.64. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $19.83. The firm has a market capitalization of $2.75 billion, a PE ratio of 3.93, a P/E/G ratio of 0.95 and a beta of 0.60.

Organon & Co. (NYSE:OGN) last released its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the business earned $1.12 EPS. The business’s quarterly revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Organon & Co.’s dividend payout ratio (DPR) is currently 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.